Abbott announced plans to buy Exact in November, in the largest medtech deal announced last year. Exact makes the Cologuard ...
Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites The Cancerguard test will be delivered through Exact Sciences’ expansive commercial and operational infrastructure, ...
ComboMATCH trials will use Exact Sciences' (EXAS) new OncoExTra™ therapy selection test to analyze tumor samples for participants in this large precision medicine initiative Participation in trials ...
Exact SciencesEXAS stock crashed Wednesday after the company inked a deal for the exclusive rights to Freenome's blood-based colon cancer test. The news comes alongside a second-quarter beat-and-raise ...
Primary study sites Baylor Scott & White Health in Texas and Endeavor Health in Illinois aim to enroll up to 25,000 patients from diverse backgrounds, assessing the impact of MCED testing on clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results